This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: University of Ulster. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Bridgeen Callan: Innovator in Cancer Treatment
Introduction
Bridgeen Callan is a notable inventor based in Ballycastle, GB. She has made significant contributions to the field of cancer treatment through her innovative research and development. Her work focuses on creating effective solutions for combating melanoma, a serious form of skin cancer.
Latest Patents
Bridgeen Callan holds 1 patent for her invention titled "Sensitizer-peptide conjugate." This invention relates to a sensitizer-peptide conjugate designed for use in the treatment of cancer. Specifically, it addresses the treatment of melanoma. The patent also discusses the application of this sensitizer-peptide conjugate in photodynamic therapy and sonodynamic therapy. The conjugate comprises at least one sensitizer and at least one peptide, showcasing her innovative approach to cancer treatment.
Career Highlights
Bridgeen Callan is affiliated with the University of Ulster, where she continues her research and development efforts. Her work has garnered attention for its potential impact on cancer therapies, particularly in enhancing treatment efficacy for melanoma patients.
Collaborations
Some of her notable coworkers include John Francis Callan and Anthony Patrick McHale. Their collaborative efforts contribute to the advancement of research in the field of cancer treatment.
Conclusion
Bridgeen Callan's innovative work in developing a sensitizer-peptide conjugate represents a significant advancement in cancer treatment. Her contributions are vital in the ongoing fight against melanoma, and her research continues to inspire future innovations in the medical field.